Genesis Drug Discovery & Development

Custom cell line development services to support preclinical research and discovery programs.

Preclinical and translational science services to understand the relationship between dose, exposure, and effect, guiding dosing strategies and clinical dose-escalation.

Early and comprehensive characterization of the active pharmaceutical ingredient (API) including impurity profile, analytical methods, and release specifications.

Expert medicinal chemistry services to optimize a lead series based on potency, selectivity, and desired properties using an integrated drug discovery platform.

Assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of compounds in vitro early in the drug discovery process.

Genesis Drug Discovery & Development provides Liquid Chromatography-Mass Spectrometry (LCMS) services combining liquid chromatography separation with mass spectrometry detection for high sensitivity and selectivity in compound identification, in vitro ADME assays, and pharmacokinetic bioanalysis.

Expert services in drug discovery, process chemistry, and custom synthesis provided by Genesis Drug Discovery & Development (GD3).

Early stage hit-to-lead chemistry services including hit confirmation, hit expansion, preliminary ADME assessment, and SAR evaluation.

Chemical process development service focused on route scouting after identifying a target molecule, evaluating potential synthetic strategies, and producing large quantities of the molecule for preclinical and clinical research.

Genesis Drug Discovery and Development (GD3) Disease Modeling Division specializes in translational studies and the evaluation of therapeutic candidates in rodent models of human disease, providing customized and standard preclinical in vivo pharmacology services.

Preclinical service to understand on-target and off-target pharmacodynamic effects of therapeutics, support proof-of-concept validation, and select development candidates.

In vitro drug metabolism and pharmacokinetics studies providing comprehensive ADME assays for small and large molecules.

Comprehensive preclinical pharmacokinetic and drug metabolism studies for rodents and rabbits, specializing in systemic and ocular research for small and large molecules.

Structure-based drug design (SBDD) services leveraging X-ray crystallography, molecular modeling, and biophysical analysis to accelerate lead optimization and identify potent, selective small molecule ligands.

Custom services to develop stable transgenic cell lines with varying expression levels using lentivirus containing target genes.

Compound scale-up services from milligram to kilogram to advance drug discovery projects and support pre-IND studies and GMP API manufacture.

Tissue extraction and processing services to study the localization of therapeutics after leaving the bloodstream, available in non-diseased or diseased animals.

Custom knockout and knock-in cell lines generated for different genes in mouse or human cell lines using CRISPR gene editing.

High-speed synthesis techniques and automated systems designed to accelerate the discovery of new compounds and screen for optimal process conditions.

Tailored assay development services including sample analysis, method validation under FDA GLP guidelines, method qualification, and method transfer.

Preclinical in vivo rodent disease model service for allergic conjunctivitis established via topical administration of Compound 48/80 in rabbits.

In-depth, disease-oriented phenotyping assessment and phenotypic characterization of genetically modified animals for drug target validation and discovery.

Custom metabolite synthesis services for Phase I and II metabolism, producing metabolites directly from drug candidates for safety assessment studies.

Atherosclerosis rodent model for evaluating cardiovascular disease therapeutics.

Comprehensive in vitro assay development services including biochemical assays, ligand binding assays, immunogenicity, cell-based assays, and cell line development.

Comprehensive molecular biology laboratory services leveraging deep expertise in pharmaceuticals, biotechnology, and CROs, offering a diverse range of nucleic acid-based assays supporting preclinical and clinical research.

Custom reporter cell lines created using genetic engineering to provide real-time insights into gene expression, signaling pathways, and cellular responses.

Genesis Drug Discovery & Development provides asymmetric synthesis services to favor the formation of specific stereoisomers for chiral drug candidates.

Evaluation of tolerability and toxicology of therapeutics including preliminary investigations for dose selection and non-GLP toxicology assessments.

Preclinical oncology service evaluating test compounds in cell line-derived (CDX), mouse and rat syngeneic, and in humanized (huMice) models to monitor therapeutics on primary and metastatic tumor growth in vivo.

GCMS analytical chemistry service for the separation, identification and quantitative analysis of individual components of a sample.

Streptozotocin-induced diabetic rodent model for evaluating diabetes therapeutics.

An in vivo mouse model using surgical optic nerve crush to induce retinal ganglion cell death for studying glaucoma, traumatic optic neuropathies, neurodegeneration, and evaluating potential therapeutics.

Functional and cell-based assay development services for custom discovery challenges.

An in vivo preclinical model that reproduces wet age-related macular degeneration (wet AMD) pathology through intravitreal administration of vascular endothelial growth factor (VEGF), supported by longitudinal ocular imaging and biomarker analyses.

Custom immunogenicity assay development services to support drug development programs.

HPLC quantitative method development services to determine concentration and purity of compounds.

Chemical process development services that create a safe, consistent, and cost-effective manufacturing process by developing, optimizing, and scaling up a chemical synthesis route.

Custom biochemical assay development services for in vitro drug discovery and development programs.

Specialized ocular efficacy models and custom model development for preclinical pharmacology research.

Db/db rodent model for later stage Type II diabetes and obesity evaluation.

Preclinical toxicology services provided by Genesis Drug Discovery & Development.

High-throughput, multiplexed analysis platform utilizing electrochemiluminescence detection for simultaneous measurement of multiple analytes.

Custom preparation of specific molecular probes including fluorophores and biotinylated targets for molecular biology and chemical biology studies.

Osteoporosis model utilizing ovariectomy for bone disease therapeutic evaluation.

Custom synthesis and analysis of stable isotopically labeled compounds (2H, 13C, 15N, 34S) using analytical techniques such as 1D and 2D NMR, HPLC, and LCMS.

Custom assay development and qualification services for the detection of large molecules like antibodies, nucleic acids, and biomarkers using Meso Scale Discovery (MSD) technology and ELISA.

Assay formats including nuclease protection assay and dual hybridization assay designed for pharmacokinetic studies of oligonucleotide drugs.

Type I diabetes rodent model for autoimmune and metabolic research.

MASH and liver disease model for evaluating therapeutic efficacy in metabolic dysfunction-associated steatohepatitis.

Type II diabetes rodent model for glucohomeostasis and metabolic disease testing.

Total synthesis of specialized pro-resolving mediators like Resolvin E1 on gram scale with optimized processes for large scale production to support clinical development.

Noninvasive in vivo bioluminescence and fluorescence imaging services to monitor biological processes, disease progression, and therapeutic response in live animals.

Diet-induced obesity model representing early Type II diabetes progression.

Preclinical in vivo pharmacology service utilizing an intravitreal injection of TNFα in rabbits to induce uveitis for evaluating therapeutic candidates.

API process development service involving optimizing the manufacturing process for active pharmaceutical ingredients, devising new production methods, and refining existing processes for efficiency and cost-effectiveness.

Hypertension and thrombosis model for cardiovascular and metabolic disease research.

Customized non-GLP and GLP-compliant in vivo toxicology testing and clinical pathology services to support early program viability decisions, target liability assessment, and IND submissions.

Dose range finding studies providing a preliminary understanding of tolerability, body weight measurements, CBC analysis, and MABEL determination for preclinical compounds.

Ex vivo immunology assays performed on extracted tissues from diseased and non-diseased animals to provide essential data about drug behavior, toxicity, and potential side effects in preclinical drug discovery and development.

Semi-preparative HPLC services operating at 130 mL/min for sample purification and isolation.

Enzyme-Linked Immunosorbent Assay services used to detect and quantify proteins, antibodies, and hormones.

Services including protein extraction, electrophoresis, transfer, and visualization with expert consultation.

Rodent model for obesity evaluation featuring comprehensive measurements of energy balance, glucose homeostasis, and lipid metabolism.

An experimental animal model involving the administration of microbeads into the anterior chamber to block drainage channels within the trabecular meshwork, elevating intraocular pressure for glaucoma and ocular research.

PDX models specifically applied for immuno-oncology research and testing.

In vivo screening for drug efficacy, tumor kinetics, and animal survival studies using pancreatic cancer patient-derived xenograft models.

Esophageal, Gastric, Colorectal and liver cancer models used for histological analysis and standard of care studies.

Collection utilizing subcutaneous and disseminating implantation studies for standard of care evaluations.

Provides a detailed three-dimensional structural analysis of a small molecule by crystalizing the compound, exposing it to X-rays and then analyzing the subsequent diffraction pattern.

Genesis Drug Discovery & Development provides specialized in vitro assays and studies, including cell culture, cytotoxicity testing, and biomarker analysis for early-stage drug discovery and preclinical testing.

Sensitive and specific real-time PCR analyses on purified nucleic acid samples to assess gene copy number or normalized gene expression, including assay design and validation, sample testing, and data analysis.

Nucleic acid extraction services preparing DNA and RNA samples from animal tissues, human body fluids, and cell cultures with quality and quantity evaluation using spectrophotometry and gel electrophoresis.

Differential gene expression analysis of control and treated datasets to assess transcriptome-level differences, alternative splicing, gene fusions, and mutations.

Comprehensive adeno-associated virus (AAV) cloning and packaging services tailored to support gene and cell therapy research, ranging from small-scale in vitro experiments to large-scale pre-clinical animal studies.

Specialized HPLC method development services focused on separating and analyzing chiral compounds.

Collection featuring WES mutational and RNA-seq gene expression analysis for model selection in lung cancer and mesothelioma.

A potent small molecule inhibitor targeting group II introns in fungal RNA, developed as an antifungal agent.

Core offering for radiation therapy and drug combination studies using chemotherapies, targeted agents, and immuno-oncology drugs with whole body and focal radiation.

Provides UV-visible spectroscopy measurements using a Spectra Max 384 plus UV-visible spectrophotometer for compound characterization.

Provides optical rotation measurements using a Perkin Elmer PE-341 polarimeter equipped with both Na and Hg source lamps to determine the identity and purity of a compound.

Utilizes Xstrahl Life Sciences' industry-leading SARRP image-guided micro irradiator, incorporating high-resolution computed tomography (CT) imaging with precise radiation delivery for preclinical oncology and radiation research.

A device utilizing the rebound measuring principle with a lightweight probe to measure intraocular pressure in preclinical ocular safety and efficacy studies.